Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
C
$2.02
 Stock is Down 0.2 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 02/20/18 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
01/29/18
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse® in patients with pulmonary arterial hypertension (PAH) now exceeds 100 patients, representing more than half of the anticipated enrollment.  As previously agreed with the U.S. Food and Drug Administration (FDA), an interim analysis of this trial will be performed by the Data ... 
01/03/18
Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the first patient has been randomized into a Phase 2b study evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).  The first patient was treated at The Lung Research Center in Chesterfield, MO, by Neil A. Ettinger, M.D. The iNO-PF Phase 2b, randomized, double-blind, placebo-cont... 
11/30/17
Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors
WARREN, N.J., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Ted Wang, Ph.D., Chief Investment Officer of Puissance Capital Management, to its Board of Directors.  Bellerophon’s Board now includes 10 members. Dr. Wang is the Chief Investment Officer of Puissance Capital Management, a global asset manager founded in 2015 with offices in the U.S. and China. Puissance was the lead inve... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources